CAPTRUST Financial Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-378	Closed	-$21K	–	2859
2022 Q2	$21K	Hold	378	–	–	﹤0.01%	3342
2022 Q1	$23K	Buy	378 +158	+72%	+$9.67K	﹤0.01%	3305
2021 Q4	$12K	Hold	220	–	–	﹤0.01%	3609
2021 Q3	$12K	Sell	220 -48	-18%	-$2.85K	﹤0.01%	3498
2021 Q2	$18K	Buy	268 +42	+19%	+$3.2K	﹤0.01%	3170
2021 Q1	$17K	Buy	226 +6	+3%	+$553	﹤0.01%	3107
2020 Q4	$22K	Buy	220 +180	+450%	+$22K	﹤0.01%	2202
2020 Q3	$6K	Buy	+40	New	+$6.67K	﹤0.01%	2474

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

CAPTRUST Financial Advisors's LKFT Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2022, closing a stake of 378 shares — an estimated $21K sold.

CAPTRUST Financial Advisors first reported a position in LKFT in Q3 2020 and held it in 8 quarters. The position peaked at $23K in Q1 2022. 84 funds tracked by Wall St. Rank hold LKFT as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 378 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2022, an estimated $21K.
CAPTRUST Financial Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2020 and held it in 8 quarters.
CAPTRUST Financial Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $23K in Q1 2022.
84 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.